BARDA to Help Fund Cue Health’s Development of Portable COVID Test for Omicron
January 16, 2023
Trending News ☀️
Cue Health Stock Intrinsic Value – CUE HEALTH ($NASDAQ:HLTH) is a biotechnology company based in San Diego, California that is revolutionizing the diagnostics industry. Recently, CUE HEALTH has announced that the Biomedical Advanced Research and Development Authority (BARDA) will provide financial support to the company to facilitate the development of a portable COVID test specifically designed for omicron. Omicron is a platform that enables clinicians to quickly detect and respond to respiratory infections in minutes. The purpose of this financial support is to help CUE HEALTH speed up the development process of the portable COVID test, allowing it to be available sooner than expected. This innovation could potentially help reduce the spread of the virus, as well as reduce the burden on medical institutions by providing a quicker diagnosis.
In addition, the BARDA funding could also provide resources for CUE HEALTH’s research and development initiatives, such as the creation of an artificial intelligence-based platform that can detect and diagnose infectious diseases in real-time. This technology could further reduce the time it takes to diagnose respiratory illnesses and save lives. Overall, the financial support from BARDA will help CUE HEALTH accelerate the development of its portable COVID test specifically designed for omicron, as well as provide resources for other research and development initiatives. This could potentially improve patient outcomes, reduce the spread of the virus, and save lives.
Stock Price
On Monday, CUE HEALTH saw a significant boost in their stock price after announcing that they were receiving funding from BARDA to help develop a portable COVID test for Omicron. Right now media sentiment is mostly positive for CUE HEALTH, leading to a 9.3% rise in their stock price from the previous closing of $1.9 to the Monday open of $2.0 and close of $2.1. According to the company, this test will have the capability to detect both active and latent infections in fifteen minutes or less, which is significantly faster than the current gold standard of lab-based tests. The portable COVID test has the potential to be a game changer in the fight against the virus. It will allow healthcare providers to quickly identify active infections and then quarantine those individuals before they can potentially spread the virus.
CUE HEALTH is hopeful that their portable COVID test will be able to make a difference in combating the virus. The funding from BARDA is a step in the right direction and a sign of confidence in their research and development efforts. With any luck, this test will be available soon and will play an important role in helping to reduce the spread of coronavirus. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cue Health. More…
| Total Revenues | Net Income | Net Margin |
| 522.06 | -137.96 | -24.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cue Health. More…
| Operations | Investing | Financing |
| -51.37 | -90.5 | -10.73 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cue Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 825.04 | 235.08 | 3.95 |
Key Ratios Snapshot
Some of the financial key ratios for Cue Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -27.4% |
| FCF Margin | ROE | ROA |
| -27.2% | -14.5% | -10.8% |
VI Analysis – Cue Health Stock Intrinsic Value
CUE HEALTH is a company whose fundamentals reflect its long term potential. The VI app has made it easy to analyze the company’s performance. According to VI Line, the fair value of CUE HEALTH share is around $5.1. However, the stock is currently being traded at $2.1, which is a massive 59% lower than the fair value. This makes it an attractive buy as the company is undervalued and offers a lot of upside potential in the long run. Investors should take this opportunity to buy the stock and take advantage of the bargain. This would bring them good returns in the future when the stock is valued at its fair price. More…
VI Peers
The healthcare industry is intensely competitive, with companies vying for market share in a variety of ways.
– Galileo Life Sciences Inc ($OTCPK:MDRM)
Galileo Life Sciences Inc is a publicly traded company with a market capitalization of 2.93M as of 2022. The company’s return on equity, a measure of profitability, is 199.87%. Galileo Life Sciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of cancer and other serious diseases. The company’s lead product candidate is a small molecule inhibitor of the PI3K/mTOR pathway, which is in clinical development for the treatment of advanced solid tumors.
– Privia Health Group Inc ($NASDAQ:PRVA)
Privately held Privia Health Group, Inc. is a national physician organization that partners with hospitals, health plans, and health systems to improve clinical and financial outcomes. The company provides a range of services, including population health management, care coordination, and revenue cycle management. Privia also offers a suite of technology solutions to help its partners deliver high-quality, cost-effective care.
– LifeStance Health Group Inc ($NASDAQ:LFST)
LifeStance Health Group Inc is a healthcare company with a focus on mental health and addiction. The company has a market cap of 2.92B as of 2022 and a Return on Equity of -14.92%. The company’s main offerings include outpatient mental health services, residential treatment facilities, and recovery support services. The company has been operational for over 20 years and has a presence in multiple states across the US.
Summary
Cue Health has been making headlines recently in the investment world, after receiving funding from the Biomedical Advanced Research and Development Authority (BARDA). Media sentiment appears to be mostly positive, and the stock price of Cue Health has increased since the news was announced. Investors should be aware that this is an early stage company and that investing in stocks carries an inherent risk.
Additionally, it is important to conduct research into the company’s financials and management team before investing. Overall, Cue Health could be an interesting investment opportunity for those who are looking for long-term growth in the medical field.
